(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 December 1999 (02.12.1999)

PCT

(10) International Publication Number
WO 99/61040 A3

(51) International Patent Classification[6]: A61K 38/00, 39/00, 31/445, C12N 15/00

(21) International Application Number: PCT/US99/11073

(22) International Filing Date: 19 May 1999 (19.05.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/086,587	22 May 1998 (22.05.1998)	US
09/088,766	2 June 1998 (02.06.1998)	US
09/150,485	9 September 1998 (09.09.1998)	US

(71) Applicant: BOYS TOWN NATIONAL RESEARCH HOSPITAL [US/US]; 555 North 30th Street, Omaha, NE 68131 (US).

(72) Inventor: COSGROVE, Dominic; 5612 Howard Street, Omaha, NE 68106 (US).

(74) Agent: MUETING, Ann, M.; Mueting, Raasch, Gebhardt, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

(88) Date of publication of the international search report:
27 January 2000

(48) Date of publication of this corrected version:
1 February 2001

(15) Information about Correction:
see PCT Gazette No. 05/2001 of 1 February 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 99/61040 A3

(54) Title: USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

(57) Abstract: The present invention provides methods for treating (i.e., delaying the onset of, slowing the progression of, and/or reversing) kidney disorders (e.g., renal glomerulonephritis and/or renal fibrosis). Certain of these methods involve administering an α1β1 integrin receptor inhibitor optionally in combination with a TGF-β1 inhibitor. The present invention also provides a mouse model for kidney disease wherein the mouse does not express a normal collagen type 4 composition in the GBM (i.e., it does not incorporate collagen α3(IV), α(IV), and α5(IV) chains into its glomerular basement membrane) and does not express the α1β1 integrin receptor.